Paul Tudor Jones Aravive, Inc. Transaction History

Tudor Investment Corp Et Al

  • $19.2 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019
SELL
$3.23 - $8.7 $41,230 - $111,055
-12,765 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$8.4 - $12.6 $107,226 - $160,839
12,765 New
12,765 $18,000

Others Institutions Holding ARAV

# of Institutions
2
Shares Held
28.1K
Call Options Held
0
Put Options Held
0
View Full List

About Aravive, Inc.

ARAV Quotes by TradingView
  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email